SORT BY:     Most Recent      Most Viewed
  • July 1, 2007

    Tegaserod (Zelnorm—Novartis)—whose sales were suspended in March 2007—is returning to the U.S. market under an investigational drug protocol for the treatment of irritable...

  • April 1, 2007

    Novartis suspended all sales and marketing of tegaserod (Zelnorm) in late March in response to an FDA request. Tegaserod has been linked to an increased incidence of cardiovascular ischemic...

  • January 1, 2007

    Proton pump inhibitors (PPIs), especially when given at high doses and for longer than 1 year, increase the risk of hip fracture, particularly in patients with comorbid conditions and in men to...

  • November 1, 2006

    Several outbreaks of Clostridium difficile–associated disease (CDAD) have recently been reported in the United States in a variety of high- and low-risk patients. Because proton...

  • October 1, 2006

    The toothbrush of a person infected with hepatitis C virus (HCV) really is a source of potential transmission, according to a recently published myth-versus-reality study. In a study of 30 HCV-...